OX2R activation induces PKC-mediated ERK and CREB phosphorylation

Experimental Cell Research

Volumn 318, Issue 16, 2012, Pages 2004-2013

  Guo, Yang ^a   Feng, Pingfu ^a,b  

^a LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CREB; ERK; MAPK signaling; Orexin; OX2R

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; CALMODULIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; OREXIN 2 RECEPTOR; OREXIN A; OREXIN B; PHOSPHOTRANSFERASE; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL LINE; CHO CELL; ENZYME PHOSPHORYLATION; HYPOTHALAMUS; INTRACELLULAR SIGNALING; MOUSE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REACTION TIME;

ANIMALIA;

EID: 84864312233     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2012.04.015     Document Type: Article

References (73)

1. de Lecea L., Kilduff T.S., Peyron C., Gao X., Foye P.E., Danielson P.E., Fukuhara C., Battenberg E.L., Gautvik V.T., Bartlett F.S., Frankel W.N., van den Pol A.N., Bloom F.E., Gautvik K.M., Sutcliffe J.G. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl. Acad. Sci. USA 1998, 95:322-327.
2. Selbach O., Haas H.L. Hypocretins: the timing of sleep and waking. Chronobiol. Int. 2006, 23:63-70.
3. Bonnavion P., de Lecea L. Hypocretins in the control of sleep and wakefulness. Curr. Neurol. Neurosci. Rep. 2010, 10:174-179.
4. Nunez A., Rodrigo-Angulo M.L., Andres I.D., Garzon M. Hypocretin/Orexin neuropeptides: participation in the control of sleep-wakefulness cycle and energy homeostasis. Curr. Neuropharmacol. 2009, 7:50-59.
5. Willie J.T., Chemelli R.M., Sinton C.M., Yanagisawa M. To eat or to sleep? Orexin in the regulation of feeding and wakefulness. Annu. Rev. Neurosci. 2001, 24:429-458.
6. Tsuneki H., Wada T., Sasaoka T. Role of orexin in the regulation of glucose homeostasis. Acta Physiol. (Oxf) 2010, 198:335-348.
7. Tsujino N., Sakurai T. Orexin/hypocretin: a neuropeptide at the interface of sleep, energy homeostasis, and reward system. Pharmacol. Rev. 2009, 61:162-176.
8. Kondo H., Kanbayashi T., Shimizu T. Orexin nervous system and narcolepsy. Nihon Naika Gakkai Zasshi 2006, 95:748-755.
9. Wurtman R.J. Narcolepsy and the hypocretins. Metabolism 2006, 55:S36-39.
10. Berezinska M., Zawilska J.B. Hypocretins: involvement in the regulation of sleep-wakefulness cycle and pathogenesis of narcolepsy. Postepy Hig. Med. Dosw. (Online) 2007, 61:1-12.
11. Ritchie C., Okuro M., Kanbayashi T., Nishino S. Hypocretin ligand deficiency in narcolepsy: recent basic and clinical insights. Curr. Neurol. Neurosci. Rep. 2010, 10:180-189.
12. Feng P., Vurbic D., Wu Z., Hu Y., Strohl K.P. Changes in brain orexin levels in a rat model of depression induced by neonatal administration of clomipramine. J. Psychopharmacol. 2008, 22:784-791.
13. Allard J.S., Tizabi Y., Shaffery J.P., Trouth C.O., Manaye K. Stereological analysis of the hypothalamic hypocretin/orexin neurons in an animal model of depression. Neuropeptides 2004, 38:311-315.
14. Scott M.M., Marcus J.N., Pettersen A., Birnbaum S.G., Mochizuki T., Scammell T.E., Nestler E.J., Elmquist J.K., Lutter M. Hcrtr1 and 2 signaling differentially regulates depression-like behaviors. Behav. Brain Res. 2011, 222:289-294.
15. Salomon R.M., Ripley B., Kennedy J.S., Johnson B., Schmidt D., Zeitzer J.M., Nishino S., Mignot E. Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects. Biol. Psychiatry 2003, 54:96-104.
16. Brundin L., Bjorkqvist M., Petersen A., Traskman-Bendz L. Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder. Eur. Neuropsychopharmacol. 2007, 17:573-579.
17. Ito N., Yabe T., Gamo Y., Nagai T., Oikawa T., Yamada H., Hanawa T. I.c.v. administration of orexin-A induces an antidepressive-like effect through hippocampal cell proliferation. Neuroscience 2008, 157:720-732.
18. Giedke H., Schwarzler F. Therapeutic use of sleep deprivation in depression. Sleep Med. Rev. 2002, 6:361-377.
19. Wu J., Buchsbaum M.S., Gillin J.C., Tang C., Cadwell S., Wiegand M., Najafi A., Klein E., Hazen K., Bunney W.E., Fallon J.H., Keator D. Prediction of antidepressant effects of sleep deprivation by metabolic rates in the ventral anterior cingulate and medial prefrontal cortex. Am. J. Psychiatry 1999, 156:1149-1158.
20. Vogel G.W. A review of REM sleep deprivation. Arch. Gen. Psychiatry 1975, 32:749-761.
21. Berger M., Vollmann J., Hohagen F., Konig A., Lohner H., Voderholzer U., Riemann D. Sleep deprivation combined with consecutive sleep phase advance as a fast-acting therapy in depression: an open pilot trial in medicated and unmedicated patients. Am. J. Psychiatry 1997, 154:870-872.
22. Demet E.M., Chicz-Demet A., Fallon J.H., Sokolski K.N. Sleep deprivation therapy in depressive illness and Parkinson's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 1999, 23:753-784.
23. Adrien J. Neurobiological bases for the relation between sleep and depression. Sleep Med. Rev. 2002, 6:341-351.
24. Ammoun S., Johansson L., Ekholm M.E., Holmqvist T., Danis A.S., Korhonen L., Sergeeva O.A., Haas H.L., Akerman K.E., Kukkonen J.P. OX1 orexin receptors activate extracellular signal-regulated kinase in Chinese hamster ovary cells via multiple mechanisms: the role of Ca2+ influx in OX1 receptor signaling. Mol. Endocrinol. 2006, 20:80-99.
25. Dwivedi Y., Rizavi H.S., Roberts R.C., Conley R.C., Tamminga C.A., Pandey G.N. Reduced activation and expression of ERK1/2 MAP kinase in the post-mortem brain of depressed suicide subjects. J. Neurochem. 2001, 77:916-928.
26. Feng P., Guan Z., Yang X., Fang J. Impairments of ERK signal transduction in the brain in a rat model of depression induced by neonatal exposure of clomipramine. Brain Res 2003, 991:195-205.
27. Dowlatshahi D., MacQueen G.M., Wang J.F., Reiach J.S., Young L.T. G Protein-coupled cyclic AMP signaling in postmortem brain of subjects with mood disorders: effects of diagnosis, suicide, and treatment at the time of death. J. Neurochem. 1999, 73:1121-1126.
28. Yamada S., Yamamoto M., Ozawa H., Riederer P., Saito T. Reduced phosphorylation of cyclic AMP-responsive element binding protein in the postmortem orbitofrontal cortex of patients with major depressive disorder. J. Neural Transm. 2003, 110:671-680.
29. Koch J.M., Hinze-Selch D., Stingele K., Huchzermeier C., Goder R., Seeck-Hirschner M., Aldenhoff J.B. Changes in CREB phosphorylation and BDNF plasma levels during psychotherapy of depression. Psychother. Psychosom. 2009, 78:187-192.
30. Blendy J.A. The role of CREB in depression and antidepressant treatment. Biol. Psychiatry 2006, 59:1144-1150.
31. Qi X., Lin W., Li J., Li H., Wang W., Wang D., Sun M. Fluoxetine increases the activity of the ERK-CREB signal system and alleviates the depressive-like behavior in rats exposed to chronic forced swim stress. Neurobiol. Dis. 2008, 31:278-285.
32. Smart D., Jerman J.C., Brough S.J., Rushton S.L., Murdock P.R., Jewitt F., Elshourbagy N.A., Ellis C.E., Middlemiss D.N., Brown F. Characterization of recombinant human orexin receptor pharmacology in a Chinese hamster ovary cell-line using FLIPR. Br. J. Pharmacol. 1999, 128:1-3.
33. Darker J.G., Porter R.A., Eggleston D.S., Smart D., Brough S.J., Sabido-David C., Jerman J.C. Structure-activity analysis of truncated orexin-A analogues at the orexin-1 receptor. Bioorg. Med. Chem. Lett. 2001, 11:737-740.
34. Harris D.M., Go V.L., Reeve J.R., Wu S.V. Stimulation of amylase release by Orexin is mediated by Orexin 2 receptor in AR42J cells. Pancreas 2002, 25:405-410.
35. Johansson L., Ekholm M.E., Kukkonen J.P. Regulation of OX1 orexin/hypocretin receptor-coupling to phospholipase C by Ca2+ influx. Br. J. Pharmacol. 2007, 150:97-104.
36. Nasman J., Bart G., Larsson K., Louhivuori L., Peltonen H., Akerman K.E. The orexin OX1 receptor regulates Ca2+ entry via diacylglycerol-activated channels in differentiated neuroblastoma cells. J. Neurosci. 2006, 26:10658-10666.
37. Nanmoku T., Isobe K., Sakurai T., Yamanaka A., Takekoshi K., Kawakami Y., Ishii K., Goto K., Nakai T. Orexins suppress catecholamine synthesis and secretion in cultured PC12 cells. Biochem Biophys. Res. Commun. 2000, 274:310-315.
38. Malendowicz L.K., Tortorella C., Nussdorfer G.G. Orexins stimulate corticosterone secretion of rat adrenocortical cells, through the activation of the adenylate cyclase-dependent signaling cascade. J Steroid Biochem. Mol. Biol. 1999, 70:185-188.
39. Ammoun S., Lindholm D., Wootz H., Akerman K.E., Kukkonen J.P. G-protein-coupled OX1 orexin/hcrtr-1 hypocretin receptors induce caspase-dependent and -independent cell death through p38 mitogen-/stress-activated protein kinase. J. Biol. Chem. 2006, 281:834-842.
40. Tang J., Chen J., Ramanjaneya M., Punn A., Conner A.C., Randeva H.S. The signalling profile of recombinant human orexin-2 receptor. Cell Signal 2008, 20:1651-1661.
41. Wenzel J., Grabinski N., Knopp C.A., Dendorfer A., Ramanjaneya M., Randeva H.S., Ehrhart-Bornstein M., Dominiak P., Johren O. Hypocretin/orexin increases the expression of steroidogenic enzymes in human adrenocortical NCI H295R cells. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009, 297:R1601-1609.
42. Hitomi M., Yang K., Guo Y., Fretthold J., Harwalkar J., Stacey D.W. p27Kip1 and cyclin dependent kinase 2 regulate passage through the restriction point. Cell Cycle 2006, 5:2281-2289.
43. Shoemaker J.L., Ruckle M.B., Mayeux P.R., Prather P.L. Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors. J. Pharmacol. Exp. Ther. 2005, 315:828-838.
44. Sakurai T., Amemiya A., Ishii M., Matsuzaki I., Chemelli R.M., Tanaka H., Williams S.C., Richardson J.A., Kozlowski G.P., Wilson S., Arch J.R., Buckingham R.E., Haynes A.C., Carr S.A., Annan R.S., McNulty D.E., Liu W.S., Terrett J.A., Elshourbagy N.A., Bergsma D.J., Yanagisawa M. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998, 92:573-585.
45. Sato-Bigbee C., Chan E.L., Yu R.K. Oligodendroglial cyclic AMP response element-binding protein: a member of the CREB family of transcription factors. J. Neurosci. Res. 1994, 38:621-628.
46. Dash P.K., Moore A.N. Characterization and phosphorylation of CREB-like proteins in Aplysia central nervous system. Brain Res. Mol. Brain Res. 1996, 39:43-51.
47. Hisaoka K., Maeda N., Tsuchioka M., Takebayashi M. Antidepressants induce acute CREB phosphorylation and CRE-mediated gene expression in glial cells: a possible contribution to GDNF production. Brain Res. 2008, 1196:53-58.
48. Rosethorne E.M., Nahorski S.R., Challiss R.A. Regulation of cyclic AMP response-element binding-protein (CREB) by Gq/11-protein-coupled receptors in human SH-SY5Y neuroblastoma cells. Biochem. Pharmacol. 2008, 75:942-955.
49. Shaywitz A.J., Greenberg M.E. CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu. Rev. Biochem. 1999, 68:821-861.
50. Deisseroth K., Bito H., Tsien R.W. Signaling from synapse to nucleus: postsynaptic CREB phosphorylation during multiple forms of hippocampal synaptic plasticity. Neuron 1996, 16:89-101.
51. Shin H.S., Cho H.S., Sung K.W., Yoon B.J. Orexin-A increases cell surface expression of AMPA receptors in the striatum. Biochem. Biophys. Res. Commun. 2009, 378:409-413.
52. Asahi S., Egashira S., Matsuda M., Iwaasa H., Kanatani A., Ohkubo M., Ihara M., Morishima H. Development of an orexin-2 receptor selective agonist, [Ala(11), D-Leu(15)]orexin-B. Bioorg Med Chem. Lett. 2003, 13:111-113.
53. Cruz C.D., Cruz F. The ERK 1 and 2 pathway in the nervous system: from basic aspects to possible clinical applications in pain and visceral dysfunction. Curr. Neuropharmacol. 2007, 5:244-252.
54. Qi X., Lin W., Li J., Pan Y., Wang W. The depressive-like behaviors are correlated with decreased phosphorylation of mitogen-activated protein kinases in rat brain following chronic forced swim stress. Behav. Brain Res. 2006, 175:233-240.
55. Dwivedi Y., Rizavi H.S., Zhang H., Roberts R.C., Conley R.R., Pandey G.N. Aberrant extracellular signal-regulated kinase (ERK)1/2 signalling in suicide brain: role of ERK kinase 1 (MEK1). Int. J. Neuropsychopharmacol. 2009, 12:1337-1354.
56. Gourley S.L., Wu F.J., Kiraly D.D., Ploski J.E., Kedves A.T., Duman R.S., Taylor J.R. Regionally specific regulation of ERK MAP kinase in a model of antidepressant-sensitive chronic depression. Biol. Psychiatry 2008, 63:353-359.
57. Gass P., Riva M.A. CREB, neurogenesis and depression. Bioessays 2007, 29:957-961.
58. Vaidya V.A., Duman R.S. Depresssion-emerging insights from neurobiology. Br. Med. Bull. 2001, 57:61-79.
59. Nair S.G., Golden S.A., Shaham Y. Differential effects of the hypocretin 1 receptor antagonist SB 334867 on high-fat food self-administration and reinstatement of food seeking in rats. Br. J. Pharmacol. 2008, 154:406-416.
60. Kageyama K., Akimoto K., Suda T. Corticotrophin-releasing factor gene transcription is directly activated after deprivation of glucocorticoids in hypothalamic cells. J. Neuroendocrinol. 2010, 22:971-978.
61. Wallace D.L., Han M.H., Graham D.L., Green T.A., Vialou V., Iniguez S.D., Cao J.L., Kirk A., Chakravarty S., Kumar A., Krishnan V., Neve R.L., Cooper D.C., Bolanos C.A., Barrot M., McClung C.A., Nestler E.J. CREB regulation of nucleus accumbens excitability mediates social isolation-induced behavioral deficits. Nat. Neurosci. 2009, 12:200-209.
62. Pandey G.N., Dwivedi Y., Ren X., Rizavi H.S., Roberts R.C., Conley R.R. Cyclic AMP response element-binding protein in post-mortem brain of teenage suicide victims: specific decrease in the prefrontal cortex but not the hippocampus. Int. J. Neuropsychopharmacol. 2007, 10:621-629.
63. Ciafaloni E., Mignot E., Sansone V., Hilbert J.E., Lin L., Lin X., Liu L.C., Pigeon W.R., Perlis M.L., Thornton C.A. The hypocretin neurotransmission system in myotonic dystrophy type 1. Neurology 2008, 70:226-230.
64. Yamada M., Tanabe K., Wada K., Shimoke K., Ishikawa Y., Ikeuchi T., Koizumi S., Hatanaka H. Differences in survival-promoting effects and intracellular signaling properties of BDNF and IGF-1 in cultured cerebral cortical neurons. J. Neurochem. 2001, 78:940-951.
65. Dwivedi Y., Rao J.S., Rizavi H.S., Kotowski J., Conley R.R., Roberts R.C., Tamminga C.A., Pandey G.N. Abnormal expression and functional characteristics of cyclic adenosine monophosphate response element binding protein in postmortem brain of suicide subjects. Arch. Gen. Psychiatry 2003, 60:273-282.
66. Hill S.M., Frasch T., Xiang S., Yuan L., Duplessis T., Mao L. Molecular mechanisms of melatonin anticancer effects. Integr. Cancer Ther. 2009, 8:337-346.
67. Uramura K., Funahashi H., Muroya S., Shioda S., Takigawa M., Yada T. Orexin-a activates phospholipase C- and protein kinase C-mediated Ca2+ signaling in dopamine neurons of the ventral tegmental area. Neuroreport 2001, 12:1885-1889.
68. Ozcan M., Ayar A., Serhatlioglu I., Alcin E., Sahin Z., Kelestimur H. Orexins activates protein kinase C-mediated Ca(2+) signaling in isolated rat primary sensory neurons. Physiol. Res. 2010, 59:255-262.
69. Xu R., Roh S.G., Gong C., Hernandez M., Ueta Y., Chen C. Orexin-B augments voltage-gated L-type Ca(2+) current via protein kinase C-mediated signalling pathway in ovine somatotropes. Neuroendocrinology 2003, 77:141-152.
70. Ziolkowska A., Spinazzi R., Albertin G., Nowak M., Malendowicz L.K., Tortorella C., Nussdorfer G.G. Orexins stimulate glucocorticoid secretion from cultured rat and human adrenocortical cells, exclusively acting via the OX1 receptor. J. Steroid Biochem. Mol. Biol. 2005, 96:423-429.
71. Nakamura Y., Miura S., Yoshida T., Kim J., Sasaki K. Cytosolic calcium elevation induced by orexin/hypocretin in granule cell domain cells of the rat cochlear nucleus in vitro. Peptides 2010, 31:1579-1588.
72. Toullec D., Pianetti P., Coste H., Bellevergue P., Grand-Perret T., Ajakane M., Baudet V., Boissin P., Boursier E., Loriolle F., Duhamelll L., Charon D., Kirilovsky J. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J. Biol. Chem. 1991, 266:15771-15781.
73. Le Panse R., Coulomb B., Mitev V., Bouchard B., Lebreton C., Dubertret L. Differential modulation of human fibroblast and keratinocyte growth by the protein kinase C inhibitor GF 109203X. Mol. Pharmacol. 1994, 46:445-451.